Option chain shows key data for Akanda's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Akanda.

Akanda (NASDAQ:AKAN) Stock, Option Chain

Akanda

Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The Company has three reportable segments: Cultivation, Distribution, and Corporate. Cultivating activities comprise the cultivation segment made up of the medical cannabis cultivation operations at RPK/Holigen in Portugal, and medical cannabis cultivation activities. Distributing activities relate to the distribution of medical cannabis by Canmart Ltd in the United Kingdom. Corporate activities entail head office costs and other general corporate expenses related to the administration of the broader group.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AKAN

CETX

ISRG

JDZG

JTAI

MGPI

MTEM

NFLX

NKGN

NTBL

NUZE

OLMA

ORGS

PEGY

SOBR

STAF

TNON

VSME

VTAK

YCBD

Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

movers image

AEHR

AMLI

CMND

CTCX

GLXG

GRTS

KDLY

LILM

LKCO

LUXH

MLGO

MNTS

NIVF

TSLA

ZENA

Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

xr:d:DAFqe777JJc:2,j:3049335502123804312,t:23080311

AMZN

DASH

GPAK

INTC

LXRX

MELI

MUFG

OPEN

OSTX

PCOR

PITA

SNAP

TEAM

TNDM

VCNX

VINE

VSEE

XCUR

Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

Akanda Corp

RBC Capital analyst Arun Viswanathan maintains Berry Global Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) with a Sector Perform and raises the price target from $69 to $73.

Price Target

Analyst Ratings

BERY

RBC Capital Maintains Sector Perform on Berry Global Gr, Raises Price Target to $73

Oppenheimer analyst Michael Phillips initiates coverage on Intl General Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGIC#NASDAQ">IGIC</a>) with a Outperform rating and announces Price Target of $30.

Initiation

IGIC

Oppenheimer Initiates Coverage On Intl General Insurance with Outperform Rating, Announces Price Target of $30

SKK Shares Halted On Circuit Breaker To The Upside, Stock Now Up 123.5%

RBC Capital analyst Elvira Scotto reiterates EnLink Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENLC#NYSE">ENLC</a>) with a Sector Perform and maintains $15 price target.

Reiteration

ENLC

RBC Capital Reiterates Sector Perform on EnLink Midstream, Maintains $15 Price Target

JP Morgan analyst Christopher Horvers maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Neutral and lowers the price target from $167 to $139.

JP Morgan Maintains Neutral on Target, Lowers Price Target to $139

SKK Shares Resume Trade Following Circuit Breaker Halt

<ul>
<li>"Channel Therapeutics" reflects the Company's focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulation</li>
<li>New name is in advance of multiple near-term data readouts</li>
</ul>
&nbsp;
Therapeutic Program Update:
<ul>
<li>Depot Program for Postoperative Nerve Blocks – the Company showed a sustained release of drug over a 96-hour period in animals and is currently performing efficacy studies in animals, with results expected imminently. &nbsp;</li>
<li>Eye Pain Program – the eye drops were well tolerated in an animal study and the Company is performing efficacy studies in animal models of eye pain with toxicology studies starting shortly. The results of the efficacy studies are expected in the coming weeks and the toxicology data is expected in late Q1 2025. The Company expects to commence Phase II human proof of concept studies in Q2 2025, with a readout by the end of 2025. &nbsp;</li>
<li>Chronic Pain – the Company is exploring program-specific financing for this program with expectations that the program will be kicked off in Q1 2025.</li>
</ul>

Biotech

General

CHRO

Chromocell Announces Name Change To "Channel Therapeutics Corporation"; Provides Therapeutic Program Updates

JP Morgan analyst Anupam Rama maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and lowers the price target from $105 to $102.

RARE

JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $102

Polymarket bettors are speculating on Bitcoin&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) performance this November, with sharp focus on whether the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42096519/bitcoin-to-reach-190000-this-cycle-michael-terpin-of-transform-group-says">cryptocurrency will surpass $100,000.</a>
Current predictions on the platform <a href="https://polymarket.com/event/will-bitcoin-hit-100k-in-november">show</a> a 79% chance that Bitcoin will breach this milestone, fueled by the asset's recent all-time high of $98,310 and growing optimism in the market.
<h3 class="wp-block-heading">Bettors Lean Toward $105,000, Cautious Beyond</h3>
Beyond the $100,000 mark, Polymarket data <a href="https://polymarket.com/event/what-price-will-bitcoin-hit-in-november">indicates</a> a 46% probability for Bitcoin to hit $105,000 in November, while a rise to $110,000 is pegged at 25%.
However, optimism dims for more ambitious targets—only 9% of bettors see Bitcoin reaching $120,000, and just 1% believe it could hit $150,000 this month.
The cautious sentiment for extreme price hikes highlights the market's view of Bitcoin's upward limits this month, even as the cryptocurrency has shown consistent growth.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42109267/bitcoin-hits-new-all-time-high-above-98000-as-spot-etfs-crack-100-billion-net-asset-value-milestone">Bitcoin Hits New All-Time High Above $98,000 As Spot ETFs Crack $100 Billion Net Asset Value Milestone</a>
<h3 class="wp-block-heading">Institutional Activity And ETF Inflows Boost Optimism</h3>
Bitcoin's rally is being bolstered by significant institutional activity. 
For example, MicroStrategy&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) plans to raise $2.6 billion to purchase more Bitcoin has pushed its market cap past $100 billion. 
Additionally, U.S. Bitcoin spot ETFs recorded $1.84 billion in net inflows over the past three days, showcasing rising demand <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42109267/bitcoin-hits-new-all-time-high-above-98000-as-spot-etfs-crack-100-billion-net-asset-value-milestone">for Bitcoin as an asset class.</a>
These developments, combined with easing global monetary policies, are likely contributing to the bullish outlook for Bitcoin's price trajectory.
Bitcoin isn't the only cryptocurrency drawing attention. Polymarket bettors are also speculating on Ethereum and Solana's November performance. 
For Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), there's a 23% <a href="https://polymarket.com/event/what-price-will-ethereum-hit-in-november">chance </a>of hitting $4,000 in Novem, while Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) bettors assign a 47% <a href="https://polymarket.com/event/what-price-will-solana-hit-in-november?tid=1732196501984">probability </a>to the token crossing $275.
These markets indicate an overall bullish sentiment across major cryptocurrencies.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42071904/blackrock-sees-renewed-sense-of-optimism-around-bitcoin">BlackRock Sees &#8216;Renewed Sense Of Optimism&#8217; Around Bitcoin</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

MSTR

Bitcoin Price Hitting $100,000 In November? Polymarket Traders Speculate It Might Go Even Higher

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul>
<li>Dividend Yield: 6.74%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $28 to $30 on July 31. This analyst has an accuracy rate of 65%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and boosted the price target from $28 to $29 on May 2. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On Nov. 20, Pfizer announced new Chief Scientific Officer and President, Research &amp; Development.</li>
<li>Benzinga Pro's real-time newsfeed alerted to la<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">test PFE news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093509/image-218.png" alt="" class="wp-image-658993" style="width:747px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093509/image-218.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093509/image-218-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093509/image-218-768x703.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Patterson Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>)</h3>
<ul>
<li>Dividend Yield: 5.18%</li>
<li>Baird analyst Jeff Johnson maintained a Neutral rating and cut the price target from $30 to $28 on Aug. 29. This analyst has an accuracy rate of 78%.</li>
<li>Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and cut the price target from $35 to $28 on June 20. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On Nov. 13, Patterson Dental extended strategic relationship with PDS Health.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest PDCO news </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="883" height="655" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093944/image-219.png" alt="" class="wp-image-658996" style="width:685px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093944/image-219.png 883w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093944/image-219-300x223.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21093944/image-219-768x570.png 768w" sizes="(max-width: 883px) 100vw, 883px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 4.68%</li>
<li>Truist Securities analyst David Macdonald reiterated a Buy rating and cut the price target from $76 to $67 on Nov. 20. This analyst has an accuracy rate of 67%.</li>
<li>UBS analyst Kevin Celiendo maintained a Neutral rating and raised the price target from $60 to $62 on Nov. 7. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On Nov. 18, CVS Health announced the addition of four new directors to its board.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">in CVS stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="847" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220.png" alt="" class="wp-image-658999" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220.png 847w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220-300x300.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220-150x150.png 150w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21094238/image-220-768x771.png 768w" sizes="(max-width: 847px) 100vw, 847px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42103475/nvidia-deere-and-3-stocks-to-watch-heading-into-thursday">Nvidia, Deere And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

PDCO

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields

<a href="https://x.com/CitronResearch/status/1859608654590202325" title="https://x.com/CitronResearch/status/1859608654590202325">https://x.com/CitronResearch/status/1859608654590202325</a>

Short Sellers

Citron Research Posts On X ".. with Bitcoin investing easier than ever (ETFs, $COIN, $HOOD), $MSTR's volume has completely detached from BTC fundamentals. While Citron remains bullish on Bitcoin, we've hedged with a short $MSTR position.."

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Overweight and raises the price target from $33 to $38.

SNDX

JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $38

Financial giants have made a conspicuous bearish move on NVIDIA. Our analysis of options history for NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) revealed 509 unusual trades.
Delving into the details, we found 39% of traders were bullish, while 42% showed bearish tendencies. Out of all the trades we spotted, 87 were puts, with a value of $5,771,224, and 422 were calls, valued at $42,566,316.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $0.5 to $280.0 for NVIDIA over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for NVIDIA options trades today is 29645.59 with a total volume of 6,724,021.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for NVIDIA's big money trades within a strike price range of $0.5 to $280.0 over the last 30 days.
<h3>NVIDIA Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732200460_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$33.95</td>
<td>$33.75</td>
<td>$33.84</td>
<td>$150.00</td>
<td>$795.2K</td>
<td>26.7K</td>
<td>543</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$2.9</td>
<td>$2.87</td>
<td>$2.9</td>
<td>$150.00</td>
<td>$219.9K</td>
<td>57.1K</td>
<td>24.2K</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$7.85</td>
<td>$7.6</td>
<td>$7.73</td>
<td>$280.00</td>
<td>$181.7K</td>
<td>18.2K</td>
<td>539</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$3.25</td>
<td>$3.2</td>
<td>$3.25</td>
<td>$150.00</td>
<td>$158.2K</td>
<td>57.1K</td>
<td>27.9K</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$2.83</td>
<td>$2.8</td>
<td>$2.81</td>
<td>$150.00</td>
<td>$132.6K</td>
<td>57.1K</td>
<td>21.3K</td>
</tr>
</tbody>
</table>

<h3>About NVIDIA</h3>
Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.
In light of the recent options history for NVIDIA, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is NVIDIA Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 48,977,431, the NVDA's price is up by 4.01%, now at $151.74. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 90 days.</li>
</ul>
<h3>What The Experts Say On NVIDIA</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $177.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for NVIDIA, targeting a price of $175. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on NVIDIA, maintaining a target price of $170. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on NVIDIA, maintaining a target price of $167. 
&#x2A; Maintaining their stance, an analyst from Benchmark continues to hold a Buy rating for NVIDIA, targeting a price of $190. 
&#x2A; Maintaining their stance, an analyst from Melius Research continues to hold a Buy rating for NVIDIA, targeting a price of $185. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for NVIDIA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

NVDA

Decoding NVIDIA's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bearish stance on Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HOOD, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 17 options trades for Robinhood Markets.
This isn't normal.
The overall sentiment of these big-money traders is split between 29% bullish and 64%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $29,800, and 16, calls, for a total amount of $1,056,398.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $40.0 for Robinhood Markets, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Robinhood Markets's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Robinhood Markets's whale activity within a strike price range from $30.0 to $40.0 in the last 30 days. 
<h3>Robinhood Markets Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732200454_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.31</td>
<td>$2.2</td>
<td>$2.2</td>
<td>$39.00</td>
<td>$220.0K</td>
<td>2.1K</td>
<td align="right">0</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.65</td>
<td>$3.55</td>
<td>$3.65</td>
<td>$37.00</td>
<td>$146.0K</td>
<td>22.6K</td>
<td align="right">928</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.15</td>
<td>$5.05</td>
<td>$5.1</td>
<td>$34.00</td>
<td>$127.5K</td>
<td>3.4K</td>
<td align="right">257</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.91</td>
<td>$1.9</td>
<td>$1.9</td>
<td>$40.00</td>
<td>$84.7K</td>
<td>17.7K</td>
<td align="right">957</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$7.95</td>
<td>$7.5</td>
<td>$7.75</td>
<td>$30.00</td>
<td>$77.5K</td>
<td>14.8K</td>
<td align="right">105</td>
</tr>
</tbody>
</table>

<h3>About Robinhood Markets</h3>
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fractional shares, recurring investments, and IPO Access. It earns transaction-based revenues from routing user orders for options, equities, and cryptocurrencies to market makers when a routed order is executed.
Having examined the options trading patterns of Robinhood Markets, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Robinhood Markets</h3>
<ul>
<li>With a trading volume of 2,118,067, the price of HOOD is up by 2.25%, reaching $36.89.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 82 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Robinhood Markets</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $31.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Robinhood Markets with a target price of $26. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Robinhood Markets, maintaining a target price of $36. 
&#x2A; Maintaining their stance, an analyst from Deutsche Bank continues to hold a Buy rating for Robinhood Markets, targeting a price of $32. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Robinhood Markets with a target price of $24. 
&#x2A; An analyst from Needham upgraded its action to Buy with a price target of $40. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Robinhood Markets, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

HOOD

Decoding Robinhood Markets's Options Activity: What's the Big Picture?

JP Morgan analyst Harlan Sur maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Overweight and raises the price target from $155 to $170.

JP Morgan Maintains Overweight on NVIDIA, Raises Price Target to $170

WORX

SCWorx Shares Halted On Circuit Breaker To The Upside, Stock Now Up 155.1%

<a href="https://www.benzinga.com/startups/24/11/42038731/jamie-dimon-warns-of-stagflation-looming-on-the-horizon-heres-the-financial-plan-experts-say-you-should-put-into-action-now">Jamie Dimon</a>, Chairman and CEO of JPMorgan Chase, has recently made headlines with his candid response to speculation about joining the federal government. While speaking at the APEC CEO Summit in Peru, Dimon addressed comments from <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42056899/jim-cramer-thinks-trumps-plans-for-robotaxis-are-fanciful-but-he-is-still-bullish-on-tesla-stock-the-musk-premium-will-work-its-magic-in-other-ways">President-elect Donald Trump</a>, who said that while he respected Dimon, Dimon would not be in the Treasury Secretary role in the incoming administration.
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a></li>
</ul>
Dimon responded to the remarks, saying, "First of all, I wish the president well and thank you – that&#8217;s a very nice note. But I just want to tell the president also, I haven&#8217;t had a boss in 25 years. I&#8217;m not about ready to start."
Despite his disinterest in joining the Trump administration, Dimon offered insights into U.S. markets&#8217; direction and global economic policy. He acknowledged that the market response to Trump's election indicated a positive outlook, with investors hopeful about potential growth opportunities, including deregulation and tax reforms.&nbsp;
Dimon emphasized that the U.S. needs a long-term growth strategy to foster a stronger economy. "I think collaboration between government and business is the way to have growth," Dimon stated. He also supported a <a href="https://www.benzinga.com/startups/24/11/42041651/kevin-oleary-biden-harris-regulations-held-back-energy-but-markets-now-celebrate-expansion">deregulatory environment</a>, clarifying that this does not mean eliminating regulations entirely.&nbsp;
Trending: With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai-2">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in the next few days</a>!
Instead, Dimon said that many regulations, particularly in countries like the U.S. and Peru (where he was speaking), have stifled growth. He suggested that inefficient regulatory environments are a major cause of this.&nbsp;
One area Dimon touched on in particular was the permitting process. He noted that inefficient government processes, including permit delays, can harm economic expansion. "I applaud any government that says I&#8217;m going to make government more efficient," Dimon remarked, stressing that improving the efficiency of government operations was essential for reducing frustrations that could fuel populism.
His leadership in the financial industry has defined Dimon's career. In 2000, he joined Bank One as its Chairman and CEO. When JPMorgan Chase merged with Bank One Corporation in 2004, Dimon was named President and COO of the newly merged organization. In 2006, Dimon became <a href="https://www.benzinga.com/startups/24/11/42024453/if-youre-in-a-knife-fight-you-better-damn-well-bring-a-knife-jpmorgan-ceo-jamie-dimon-calls-for-a-stand-against-regulation">CEO of JPMorgan Chase</a>, adding Chairman of the Board to his extensive resume only a year later.&nbsp;
See Also: This rooftop wind turbine is taking on a market projected to reach over $900 billion by 2032 —<a href="https://www.benzinga.com/money/halcium"> With already over 40,000 users signing up to purchase, here's a chance to be an early investor today!</a>
Dimon's career spans decades, with earlier roles at American Express, Citigroup and Travelers group, where he was known for driving significant acquisitions and navigating complex corporate environments.
As one of the most influential figures in <a href="https://www.benzinga.com/startups/24/11/41885077/can-hong-kongs-ai-framework-lead-to-more-responsible-ai-use-in-global-finance">global finance</a>, Dimon's insights into the future of economic policy will likely continue to shape discussions on financial regulation, government efficiency and the path forward for American business. For now, however, Dimon seems content to focus on his role at JPMorgan, where he has thrived without needing a boss for over two decades.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai-2"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before it closes in a few days.</a></li>
</ul>

'I Haven't Had A Boss For 25 Years, I'm Not About Ready To Start' – JPMorgan CEO Jamie Dimon Uninterested In Treasury Secretary Position

RBC Capital analyst Logan Reich maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Outperform and lowers the price target from $70 to $65.

JACK

RBC Capital Maintains Outperform on Jack In The Box, Lowers Price Target to $65

Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) launched the MAX OLED solution, a patented OLED pixel architecture and groundbreaking<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42109055/applied-materials-breakthrough-to-bring-oled-displays-to-tablets-pcs-and-tvs" rel="noreferrer noopener"> display manufacturing technology</a>.
This solution aims to bring the high-quality OLED displays found in premium smartphones to tablets, PCs, and eventually TVs.
OLED is the preferred display technology for top smartphone manufacturers due to its exceptional display quality, lightweight, flexible form factors, and durability.
However, scaling OLED display production for the larger glass panels used in tablets, PCs, and TVs has been a challenge—until now.
Applied&#8217;s MAX OLED solution simplifies the scaling of OLED manufacturing from Gen 6 to Gen 8 glass substrates, which are about twice as large, and beyond.
It also introduces a new method for depositing OLED materials, enhancing pixel brightness and resolution, reducing energy consumption, and extending the display&#8217;s lifespan.
The MAX OLED solution has generated strong customer interest, with repeat orders from several top display manufacturers.
Applied will also supply an alpha system to Samsung Display, a global leader in OLED and QD-OLED panels, for evaluation of this new technology.
Ross Young, Co-founder and CEO of Display Supply Chain Consultants (DSCC), said, &#8220;Applied Materials has developed a true breakthrough in OLED manufacturing technology that will enable better OLED displays at more attractive prices,&#8221;
&#8220;This technology has the potential to accelerate OLED adoption in a range of markets, from tablets and PCs to automobiles and micro-displays for AR/VR, creating a catalyst for the entire display industry.&#8221;
Investors can gain exposure to the stock via&nbsp;First Trust Nasdaq Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXL#NASDAQ">FTXL</a>) and Pacer BlueStar Engineering the Future ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULD#NASDAQ">BULD</a>).
Price Action: AMAT shares are up 0.90% at $172.03 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42105339/mohamed-el-erian-warns-against-simplistic-narratives-as-trump-plans-aggressive-tariff-strategy-the-issue-is-quite-complex" target="_blank" rel="noreferrer noopener">Mohamed El-Erian Warns Against Simplistic Narratives As Trump Plans Aggressive Tariff Strategy: &#8216;The Issue Is Quite Complex&#8217;</a></li>
</ul>

Equities

Large Cap

AMAT

BULD

FTXL

Breaking New Ground In OLED: Applied Materials Unveils MAX OLED Solution For Bigger Displays

Piper Sandler analyst Peter Keith maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Neutral and lowers the price target from $156 to $130.

Piper Sandler Maintains Neutral on Target, Lowers Price Target to $130

Akanda Corp (AKAN) has released an update. Akanda Corp. has addressed its previous non-compliance with Nasdaq's minimum shareholders' equity requir...

Akanda Corp Regains Nasdaq Compliance

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks this morning are earnings reports, a failed merger deal, delisting updates and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>VSee Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/">VSEE</a>) stock is rocketing more than 159% as the robot maker <a href="https://www.nasdaq.com/press-release/vsee-health-and-ava-robotics-partner-develop-telepresence-solutions-hospital">plans for telepresence solutions</a> for the inpatient intensive care market.</li>



<li>Adagio Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/adgm-stock-quote/">ADGM</a>) shares are soaring close to 36% following its <a href="https://www.businesswire.com/news/home/20240731222906/en/Adagio-Medical-Announces-the-Closing-of-the-Business-Combination-with-ARYA-IV-Creating-a-Publicly-Traded-Company-Focused-on-the-Innovative-Technologies-for-Treatment-of-Cardiac-Arrhythmias">recent public debut</a>.</li>



<li>Akanda (NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock is surging over 35% alongside heavy pre-market trading.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) shares are gaining more than 29% on a <a href="https://www.businesswire.com/news/home/20240801299565/en/Exicure-Inc.-Receives-Positive-Listing-Determination-from-Nasdaq">positive listing update</a> from the Nasdaq Capital Market.</li>



<li>Australian Oilseeds (NASDAQ:<a href="https://investorplace.com/stock-quotes/coot-stock-quote/">COOT</a>) stock is rising 25% after announcing a <a href="https://www.nasdaq.com/press-release/australian-oilseeds-announces-appointment-new-independent-auditor-2024-08-01">new independent auditor</a>.</li>



<li>Tandem Diabetes Care (NASDAQ:<a href="https://investorplace.com/stock-quotes/tndm-stock-quote/">TNDM</a>) shares are increasing nearly 25% with the release of its <a href="https://www.nasdaq.com/press-release/tandem-diabetes-care-announces-second-quarter-2024-financial-results-and-increases">Q2 earnings report</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) stock is heading over 23% higher with <a href="https://www.nasdaq.com/press-release/vaccinex-reports-positive-data-signal-ad-phase-1b-2-trial-pepinemab-alzheimers">recent clinical trial news</a>.</li>



<li>AGBA Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/agba-stock-quote/">AGBA</a>) shares are climbing more than 13% without any clear news this morning.</li>



<li>Venus Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/vero-stock-quote/">VERO</a>) stock is jumping over 13% on Friday morning.</li>



<li>Integral Ad Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/ias-stock-quote/">IAS</a>) shares are up 13% with its <a href="https://www.nasdaq.com/press-release/ias-reports-second-quarter-2024-financial-results-2024-08-01">latest earnings news</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Gamer Pakistan (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/">GPAK</a>) stock is plummeting almost 47% <a href="https://www.pr.com/press-release/917157#:~:text=(Nasdaq%3AGPAK)%20(GPAK,and%20that%20trading%20of%20the">alongside a delisting notice</a>.</li>



<li>Fresh Vine Wine (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/">VINE</a>) shares are diving more than 37% with the <a href="https://www.nasdaq.com/press-release/fresh-vine-wine-inc-and-notes-live-inc-mutually-agree-terminate-merger-agreement-2024">termination of a merger agreement</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) stock is tumbling over 30% as Badcock Home Furniture &amp; More <a href="https://nypost.com/2024/08/01/business/major-furniture-chain-badcock-to-shut-all-its-stores-after-120-years/">shuts down all of its stores</a>.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are taking a more than 24% beating on plans for a <a href="https://www.stocktitan.net/news/GNLN/greenlane-announces-board-s-approval-of-reverse-stock-split-9yehmvs5r4ed.html">reverse stock split</a>.</li>



<li>Procore Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pcor-stock-quote/">PCOR</a>) stock is dropping 22% alongside its <a href="https://www.nasdaq.com/press-release/procore-announces-second-quarter-2024-financial-results-2024-08-01">Q2 earnings report</a>.</li>



<li>Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) shares are sliding close to 21% on Friday morning.</li>



<li>Intel (NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>) stock is falling over 20% after releasing its <a href="https://www.theverge.com/2024/8/1/24210656/intel-is-laying-off-over-10000-employees-and-will-cut-10-billion-in-costs">Q2 earnings report</a>.</li>



<li>Smith Micro Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/smsi-stock-quote/">SMSI</a>) shares are decreasing more than 19% with its <a href="https://seekingalpha.com/article/4709513-smith-micro-software-inc-smsi-q2-2024-earnings-call-transcript">latest earnings report</a>.</li>



<li>GraniteShares 2x Long AMZN Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzz-stock-quote/">AMZZ</a>) stock is slipping over 17%.</li>



<li>Snap (NYSE:<a href="https://investorplace.com/stock-quotes/snap-stock-quote/">SNAP</a>) shares close out our pre-market stock movers down more than 17% <a href="https://www.cnbc.com/2024/08/01/snap-shares-plunge-over-20percent-af.html">on weak guidance</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-2nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Akanda&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock is on the rise Friday alongside heavy pre-market trading of the cannabis company&rsquo;s shares this morning.



This has more than 6.8 million shares of AKAN stock changing hands as of this writing. That&rsquo;s well above the company&rsquo;s daily average trading volume of about 1.3 million shares. It&rsquo;s also higher than Akanda&rsquo;s <a href="https://finance.yahoo.com/quote/AKAN/key-statistics/">float of 760,620 units</a>.



This increase in trading volume on Friday comes without any clear news from Akanda. That includes no press releases or filings with the Securities and Exchange Commission (SEC). There also isn&rsquo;t any analyst coverage causing today&rsquo;s rally.



One thing that traders will keep in mind is AKAN being a penny stock. This comes from its prior closing price of only $1.45 and a market capitalization of just $2.779 million.



<h2>What That Means for AKAN Stock</h2>



Investors will want to be wary of AKAN alongside today&rsquo;s rally. With the lack of news and sudden surge in trading volume, it has some signs of a pump and dump. The alternative is speculative traders boost the shares higher.



No matter the case, it makes AKAN stock a risky investment right now. That means investors will want to be careful about taking a stake in the company.



AKAN stock is up 34.1% as of Friday morning.



Investors will learn more about the most recent stock market stories below!



We have all of the hottest stock market news traders need to know about on Friday! Among that is what&rsquo;s happening with VSee Health&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/">VSEE</a>) stock up today, the biggest pre-market stock movers this morning and more. All of this info is ready to go at the links below!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/08/why-is-vsee-health-vsee-stock-up-172-today/">Why Is VSee Health (VSEE) Stock Up 172% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-2nd/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>



<li><a href="https://investorplace.com/2024/08/smci-stock-super-micro-launches-new-nvidia-offering/">SMCI Stock: Super Micro Launches New Nvidia Offering</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-akanda-akan-stock-up-34-today/">Why Is Akanda (AKAN) Stock Up 34% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Akanda (AKAN) Stock Up 34% Today?

Akanda Corp (AKAN) has released an update. Akanda Corp., a global cannabis player, has successfully acquired a hemp cultivation license in Canada, ...

Akanda Corp. Expands Canadian Cannabis Footprint

Akanda announces pricing of underwritten public offering

Akanda Corp (AKAN) has released an update. Akanda Corp., a medical cannabis company, has announced a public offering of 1.5 million shares at $1.00...

Akanda Corp's New Public Offering Aims to Raise $1.5 Million

Akanda Corp (AKAN) has released an update. Akanda Corp., an Ontario-based corporation, has entered into an underwriting agreement with Univest Secu...

Akanda Corp. Announces Public Offering of Shares

Akanda to implement reverse stock split

Akanda Corp (AKAN) has released an update. Akanda Corp. is set to execute a 1-for-2 reverse stock split on November 14, 2024, reducing its outstand...

Akanda Corp. Announces Reverse Stock Split for Shareholders

19:50 EST Akanda (AKAN) Corp trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...

Akanda Corp trading halted, news pending

ADGM

AGBA

AMZZ

CONN

COOT

ESLA

GNLN

SMSI

VERO

Press Releases

Univest Securities, LLC Announces Closing of $5 Million Underwritten Public Offering for its Client Akanda Corp. (NASDAQ: AKAN)

Treatment.com International Inc's (CSE: TRUE) Strategic Evolution in Health Tech

Comments

Akanda

Akanda (AKAN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga